Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHERING's SECOND PENEM (SCH 34343) IS ON SIX-MONTH HOLD

Executive Summary

SCHERING's SECOND PENEM (SCH 34343) IS ON SIX-MONTH HOLD in early clinical testing as the result of "certain recent toxicological findings in animals," Schering-Plough Exec VP Richard Kogan reported during a June 20 session with the Health Care Analysts of New York. Kogan described the antibiotic as "a product clearly superior to all known agents in treating anerobic infections." SCH 34343 entered Phase I trials in May 1984, and reportedly had progressed into Phase II studies before the halt. Kogan told the analysts that Schering is still expecting to file an NDA "in the second half of 1986." Kogan explained the delay: "As of now, we believe this will be a six-month delay. The initial oral penem was dropped from clinical trials in 1983." Closest to the market among the new Schering Rx products is the sedative/hypnotic, quazepam. The NDA for quazepam could be approved late in 1985 or early next year, the firm says. The company describes quazepam as avoiding rebound insomnia and yielding a "more natural sleep cycle"
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel